[go: up one dir, main page]

ZA200603065B - The use of anti biotics as vaccine adjuvants - Google Patents

The use of anti biotics as vaccine adjuvants

Info

Publication number
ZA200603065B
ZA200603065B ZA200603065A ZA200603065A ZA200603065B ZA 200603065 B ZA200603065 B ZA 200603065B ZA 200603065 A ZA200603065 A ZA 200603065A ZA 200603065 A ZA200603065 A ZA 200603065A ZA 200603065 B ZA200603065 B ZA 200603065B
Authority
ZA
South Africa
Prior art keywords
vaccine adjuvants
anti biotics
biotics
vaccine
adjuvants
Prior art date
Application number
ZA200603065A
Other languages
English (en)
Inventor
Michael K O'hara
Mcgavin David Ross
Leyh Randy Dean
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200603065B publication Critical patent/ZA200603065B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA200603065A 2003-11-21 2006-04-18 The use of anti biotics as vaccine adjuvants ZA200603065B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52409703P 2003-11-21 2003-11-21

Publications (1)

Publication Number Publication Date
ZA200603065B true ZA200603065B (en) 2007-08-29

Family

ID=34619630

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200603065A ZA200603065B (en) 2003-11-21 2006-04-18 The use of anti biotics as vaccine adjuvants

Country Status (16)

Country Link
US (1) US20070141086A1 (fr)
EP (1) EP1689434A1 (fr)
JP (1) JP2007512312A (fr)
KR (1) KR100785601B1 (fr)
CN (1) CN1882360A (fr)
AR (1) AR047728A1 (fr)
AU (1) AU2004290982B2 (fr)
BR (1) BRPI0416205A (fr)
CA (1) CA2546195A1 (fr)
IL (1) IL175373A0 (fr)
MX (1) MXPA06005639A (fr)
NO (1) NO20062918L (fr)
RU (1) RU2322241C2 (fr)
TW (1) TW200526245A (fr)
WO (1) WO2005049081A1 (fr)
ZA (1) ZA200603065B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
JP2006505583A (ja) 2002-10-25 2006-02-16 フォーミックス エルティーディー． 化粧剤および医薬用フォーム
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
FR2896416B1 (fr) * 2006-01-24 2010-08-13 Vetoquinol Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (fr) 2007-11-30 2009-06-04 Foamix Ltd. Peroxyde de benzoyle contenant de la mousse
WO2009090495A2 (fr) 2007-12-07 2009-07-23 Foamix Ltd. Vecteurs moussants siliconés à base d'huile et de liquide, et formulations
EP2234637A2 (fr) * 2007-12-21 2010-10-06 GlaxoSmithKline Biologicals S.A. Vaccins anti-malaria
WO2010125470A2 (fr) 2009-04-28 2010-11-04 Foamix Ltd. Véhicule moussant et compositions pharmaceutiques comportant des solvants polaires aprotiques et leurs utilisations
WO2011013008A2 (fr) 2009-07-29 2011-02-03 Foamix Ltd. Compositions hydro-alcooliques moussantes à base d'agents non tensioactifs non polymères, mousses légères, et leurs utilisations
CA2769625C (fr) 2009-07-29 2017-04-11 Foamix Ltd. Compositions hydro-alcooliques moussantes non tensioactives, mousses legeres, et leurs utilisations
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US8945516B2 (en) 2009-10-02 2015-02-03 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
EP2528620B1 (fr) * 2010-01-28 2019-06-05 Universiteit Gent Vaccin contre la salmonelle
UA114286C2 (uk) * 2011-07-22 2017-05-25 Общєство С Огранічєнной Отвєтствєнностью "Новамєдіка" Спосіб лікування staphylococcus aureus
CN105263513A (zh) * 2013-03-14 2016-01-20 王荣福 调控调节性t细胞功能的方法和组合物
CN105407915A (zh) 2013-03-15 2016-03-16 加州大学洛杉矶分校港口医学中心生物医学研究所 用于治疗真菌性和细菌性病原体的组合物和方法
CN103127098B (zh) * 2013-03-22 2014-05-14 于法周 一种含有克拉维酸或其盐的抗癌药物组合物及制药用途
EP2926815A1 (fr) * 2014-04-03 2015-10-07 Institut Curie Dérivés de céphalosporines pour traiter le cancer
WO2016065525A1 (fr) * 2014-10-28 2016-05-06 湘北威尔曼制药股份有限公司 Utilisation de composés d'amide oxopipérazinyle
CN105616414B (zh) * 2014-10-28 2019-03-05 湘北威尔曼制药股份有限公司 一种氧代哌嗪酰胺类化合物的新用途
CN104546863B (zh) * 2015-02-09 2016-09-14 江苏澳格姆生物科技有限公司 头孢噻吩钠在制备抑制肿瘤细胞转移和扩散的药物中的应用
EP3332809A4 (fr) * 2015-08-06 2019-04-10 Nitto Denko Corporation Composition favorisant l'induction d'immunité et composition pharmaceutique de vaccin
WO2017116049A1 (fr) * 2015-12-31 2017-07-06 경북대학교 산학협력단 Composition pharmaceutique pour traiter le cancer et empêcher la métastase, contenant comme principe actif un composé à base de sulfonamide
US10857216B2 (en) 2016-03-09 2020-12-08 Novadigm Therapeutics, Inc. Methods and kits for use in preventing and treating vulvovaginal candidiasis
MX377365B (es) 2016-09-08 2025-03-10 Journey Medical Corp Composiciones y métodos para tratar rosácea y acné.
CN110302376A (zh) * 2019-04-22 2019-10-08 荆门市动物疫病预防控制中心 一种禽流感疫苗佐剂及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT750907E (pt) * 1995-06-30 2002-08-30 American Cyanamid Co Formulacoes de vacinas estaveis para administracao parenterica metodo para a sua utilizacao e processo para a sua preparacao
US5929086A (en) * 1996-05-10 1999-07-27 Pharmacia & Upjohn Company Topical administration of antimicrobial agents for the treatment of systemic bacterial diseases
HN1998000086A (es) * 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
US6339063B1 (en) * 1997-09-10 2002-01-15 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
UA70972C2 (uk) * 1998-11-20 2004-11-15 Пфайзер Продактс Інк. 13-членні азаліди і їх застосування як антибіотиків

Also Published As

Publication number Publication date
EP1689434A1 (fr) 2006-08-16
WO2005049081A1 (fr) 2005-06-02
KR100785601B1 (ko) 2007-12-14
CN1882360A (zh) 2006-12-20
NO20062918L (no) 2006-08-21
AU2004290982B2 (en) 2008-06-19
IL175373A0 (en) 2006-09-05
AR047728A1 (es) 2006-02-15
CA2546195A1 (fr) 2005-06-02
BRPI0416205A (pt) 2006-12-26
AU2004290982A1 (en) 2005-06-02
KR20060091001A (ko) 2006-08-17
MXPA06005639A (es) 2006-08-17
RU2322241C2 (ru) 2008-04-20
RU2006117339A (ru) 2007-12-10
TW200526245A (en) 2005-08-16
JP2007512312A (ja) 2007-05-17
US20070141086A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
IL175373A0 (en) The use of anti biotics as vaccine adjuvants
GB0329146D0 (en) Vaccine
AU2003285320A8 (en) Vaccine
GB0323840D0 (en) Vaccines
GB0209878D0 (en) Vaccine
EP1599170A4 (fr) Adjuvant de vaccin base de lymphocytes humains
IL173921A0 (en) Vaccine
GB0305794D0 (en) Vaccine
GB0330079D0 (en) Vaccine
AP2695A (en) Vaccine adjuvants
GB0304634D0 (en) Vaccines
GB0308691D0 (en) Vaccine preparations
AU2003900767A0 (en) Idiotypic vaccine
GB0206595D0 (en) Vaccine
SI1604683T1 (sl) Vakcinski pripravki na gangliozidni osnovi za subkutano dajanje
GB0419838D0 (en) Vaccine adjuvants
GB0330007D0 (en) Vaccines
GB0300455D0 (en) Meyhod of vaccine preparation
GB0329827D0 (en) Vaccine
GB0326757D0 (en) Vaccine
GB0305028D0 (en) Vaccine
GB0223355D0 (en) Vaccine
GB0328501D0 (en) Fish vaccine
GB0222991D0 (en) Attenuated vaccine
GB0300914D0 (en) Vaccines